The prognostic value of pretreatment 2-[18F]-fluoro-2-deoxy-D- glucose positron emission tomography scan in women with cervical cancer

International Journal of Gynecological Cancer

Volumn 17, Issue 5, 2007, Pages 1062-1067

  Unger, J B ^a   Lilien, D L ^b   Caldito, G ^c   Ivy, J J ^a   Charrier, A ^a   Bellaire, B ^a  

^a Louisiana State University School of Medicine Shreveport   (United States)

^b Biomedical Research Foundation of Northwest Louisiana   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Cervical cancer; Disease free survival; FDG PET scan

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; FUROSEMIDE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISEASE FREE SURVIVAL; DRUG UPTAKE; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PARAAORTIC LYMPH NODE; PELVIS LYMPH NODE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; RISK ASSESSMENT; TREATMENT OUTCOME; UTERINE CERVIX CANCER;

ADULT; AGED; CARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; UTERINE CERVICAL NEOPLASMS;

EID: 34548672590     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.00902.x     Document Type: Article

References (20)

1. International Federation of Gynecology and Obstetrics. FIGO staging of gynecologic cancers: cervical and vulva. Int J Gynecol Cancer 1995 5 : 319 24.
2. Stehman FB, Bundy BN, DiSaia PJ, Keys HM, Larson JE, Fowler WC. Carcinoma of the cervix treated with irradiation therapy: I. A multivariate analysis of prognostic variables in the Gynecologic Oncology Group. Cancer 1991 67 : 2776 85.
3. Sugawara Y, Eisbruch A, Kosuda S, Recker BE, Kison PV, Wahl RL. Evaluation of FDG PET in patients with cervical cancer. J Nucl Med 1999 40 : 1125 31.
4. Narayan K, Hicks RJ, Jobling T, Bernshaw D, McKenzie AF. A comparison of MRI and PET scanning in surgically staged loco-regionally advanced cervical cancer: potential impact on treatment. Int J Gynecol Cancer 2001 11 : 263 71.
5. Williams AD, Cousins C, Soutter WP et al. Detection of pelvic lymph node metastases in gynecologic metastases in gynecologic malignancy: a comparison of CT, MR imaging, and positron emission tomography. Am J Roentgenol 2001 177 : 343 8.
6. Grigsby PW, Siegel BA, Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol 2001 19 : 3745 9.
7. Reinhardt MJ, Ehritt-Braun C, Vogelgesang D et al. Metastatic lymph nodes in patients with cervical cancer: detection with MR imaging and FDG PET. Radiology 2001 218 : 776 82.
8. Yen TC, Ng KK, Ma SY et al. Value of dual-phase 2-fluoro-2deoxy-D-glucose positron emission tomography in cervical cancer. J Clin Oncol 2003 21 : 3651 8.
9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958 53 : 457 81.
10. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966 50 : 163 70.
11. Rose PG, Adler LP, Rodriguez M, Faulhaber PF, Abdul-Karim FW, Miraldi F. Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. J Clin Oncol 1999 17 : 41 5.
12. 18F-FDG PET using a simple visual analysis of tumor characteristics in patients with cervical cancer. J Nucl Med 2003 44 : 192 7.
13. Unger JB, Ivy JJ, Connor GP et al. Detection of recurrent cervical cancer by whole-body FDG PET scan in asymptomatic and symptomatic women. Gynecol Oncol 2004 101 : 212 6.
14. Havrilesky LJ, Wong TZ, Secord AA, Berchuck A, Clarke-Pearson DL, Jones EL. The role of PET scanning in the detection of recurrent cervical cancer. Gynecol Oncol. 2003 90 : 186 90.
15. Minn H, Joensuu H, Ahonen A, Klemi P. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer 1988 61 : 1776 81.
16. Okada J, Yoshikawa K, Itami M et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 1992 33 : 325 9.
17. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 1993 34 : 414 9.
18. 18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest Radiol 1987 22 : 360 71.
19. Okada J, Yoshikawa K, Imazeki K et al. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. J Nucl Med 1991 32 : 686 91.
20. Nakamoto Y, Eisbruch A, Achtyes ED et al. Prognostic value of positron emission tomography using F-18-fluorodeoxyglucose in patients with cervical cancer undergoing radiotherapy. Gynecol Oncol 2002 84 : 289 95.